Study of E7386 in Participants With Selected Advanced Neoplasms
Status:
Recruiting
Trial end date:
2023-03-05
Target enrollment:
Participant gender:
Summary
This study will be conducted to assess the safety/tolerability profile of E7386 as a single
agent administered orally in participants with selected advanced or recurrent neoplasms and
to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of
E7386.